QSBS Advisor Match

QSBS in New Jersey: 2026 Conformity, 10.75% Rate Savings, and What Founders with Pre-2026 Stock Need to Know

New Jersey enacted A4455/S4503, signed June 30, 2025, bringing the state into conformity with IRC §1202 for the first time — effective for dispositions on or after January 1, 2026. Founders and investors who sell qualifying QSBS in 2026 or later can now exclude that gain from New Jersey Gross Income Tax, even if the stock was issued years before 2026. At New Jersey's top marginal rate of 10.75% — with no preferential treatment for long-term capital gains — this exclusion can eliminate over $1.6 million in state tax on a $15 million qualifying exit.

What changed: A4455 explained

New Jersey's Gross Income Tax (GIT) historically did not conform to IRC §1202. Until 2026, every dollar of gain from the sale of qualified small business stock was subject to New Jersey income tax at rates up to 10.75%, regardless of the federal exclusion. New Jersey was one of only a handful of non-conforming states, alongside California, Pennsylvania, Alabama, and Mississippi.1

Governor Phil Murphy signed A4455/S4503 into law on June 30, 2025. The bill amends New Jersey's GIT statutes to exclude from gross income any gain that is excluded at the federal level under IRC §1202. The exclusion applies for tax years beginning on or after January 1, 2026 — meaning dispositions occurring on or after January 1, 2026 qualify, even if the QSBS was acquired years earlier.2

Key timing rule: The New Jersey exclusion applies to the disposition date, not the acquisition date. If you have been holding QSBS stock since 2020 and sell it in 2026, the gain is now excluded from New Jersey GIT — assuming federal §1202 qualification is met. Gains realized in 2025 or earlier remain fully taxable in New Jersey regardless of the new law.

Rolling conformity: OBBBA changes apply in New Jersey

A4455 adopts IRC §1202 by dynamic reference, without tying conformity to a specific date. This rolling (or "dynamic") conformity means New Jersey automatically incorporates subsequent federal changes to §1202 — including the modifications made by the One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, just four days after A4455.3

In practical terms: for stock issued after July 4, 2025, the OBBBA's tiered holding period (50% exclusion at 3 years, 75% at 4 years, 100% at 5 years) and the increased $15 million cap apply at the New Jersey level, not just federally. For stock issued before July 4, 2025, the prior rules apply: 100% exclusion at 5 years, $10 million or 10× adjusted basis cap, whichever is greater.

This contrasts with Massachusetts, where a static IRC reference date means the OBBBA's enhanced terms may not be adopted at the state level. New Jersey's rolling conformity makes it structurally similar to New York and Illinois — the state follows whatever Congress enacts for §1202 without requiring separate NJ legislation for each change. See the Massachusetts QSBS guide for the OBBBA gap issue there.

Why the 10.75% rate makes NJ conformity unusually valuable

New Jersey taxes capital gains as ordinary income at the standard GIT brackets — there is no preferential long-term capital gains rate.4 The top marginal rate of 10.75% applies to taxable income above $1 million (for single and married filing jointly filers). For a founder with a significant liquidity event, effectively all of the QSBS gain falls in the 10.75% bracket.

This means the economic value of the New Jersey exclusion is:

Compare this to a state with a 5% flat rate: the same exclusion saves $500K–$750K. New Jersey's high rate without a preferential LTCG rate means the GIT exclusion has an outsized dollar value relative to most conforming states — second only to California, which still does not conform. A New Jersey founder who previously owned QSBS and deferred a sale specifically because of the NJ state tax drag may now have a significantly improved exit tax profile if the holding period has been satisfied.

What NJ conformity saves founders: worked examples

Example 1: Pre-OBBBA QSBS (issued before July 4, 2025), $10M exit, 5-year hold, $50K adjusted basis — NJ disposition in 2026

Total sale proceeds$10,000,000
Adjusted basis$50,000
Total gain$9,950,000
§1202 exclusion — 100%, 5-yr hold; 10× basis = $500K < $10M flat cap; $10M cap applies; full gain excluded$9,950,000
Federal capital gains tax$0
Federal NIIT (excluded §1202 gain is not net investment income)$0
NJ GIT under 2026 A4455 (mirrors federal exclusion)$0
Total tax on $10M exit$0

Had this sale occurred in 2025 (before NJ conformity): NJ GIT on $9.95M at 10.75% = $1,069,625 in state tax alone. NJ conformity eliminates this entirely for 2026+ dispositions.

Example 2: Larger pre-OBBBA exit ($25M), $50K basis, 5-year hold — partial exclusion scenario

Total gain$24,950,000
§1202 exclusion — 100%, 5-yr hold, $10M flat cap (10× basis = $500K < $10M)$10,000,000
Taxable gain (above $10M cap)$14,950,000
Federal LTCG at 20%$2,990,000
Federal NIIT at 3.8%$568,100
NJ GIT: mirrors federal — $10M excluded, $14.95M taxable at 10.75%$1,607,125
Total tax (2026 disposition with NJ conformity)$5,165,225

Had this occurred in 2025: NJ GIT on the full $24.95M = $2,682,125. NJ conformity saves $1,075,000 in state tax on the $10M excluded portion. The post-OBBBA $15M cap would eliminate another $537,500 in NJ tax on an additional $5M excluded — available for stock issued after July 4, 2025.

Example 3: Post-OBBBA QSBS (issued after July 4, 2025), $15M exit, 5-year hold — full exclusion

Total gain$14,950,000
§1202 exclusion — 100%, 5-yr hold, OBBBA $15M cap covers entire gain$14,950,000
Federal capital gains tax$0
Federal NIIT$0
NJ GIT (rolling conformity includes OBBBA $15M cap)$0
Total tax on $15M exit$0

Example 4: Post-OBBBA QSBS, $15M exit, 4-year hold — 28% rate trap and NJ partial inclusion

Total gain$14,950,000
§1202 exclusion at 75% (4-year OBBBA tier)$11,212,500
Non-excluded gain (25%)$3,737,500
Federal tax at 28% maximum rate — §1(h)(4)(A)(i)$1,046,500
Federal NIIT at 3.8%$142,025
NJ GIT: mirrors federal 75% exclusion; $3.74M taxable at 10.75%$401,781
Total tax at 4-year hold$1,590,306

Waiting one more year to the 5-year mark eliminates all $1,590,306. The NJ tax on the non-excluded portion ($401,781) compounds the federal 28% rate trap — the one-year timing difference between year four and year five is worth over $1.59M total for a New Jersey founder.

Without QSBS: same $15M exit, stock fails §1202 qualification

Federal LTCG at 20% on $14.95M$2,990,000
Federal NIIT at 3.8%$568,100
NJ GIT at 10.75% on $14.95M (no preferential LTCG rate)$1,607,125
Total tax without QSBS$5,165,225

For a New Jersey founder with post-OBBBA stock and a full 5-year hold, qualifying QSBS eliminates the entire $5.17M tax bill — $3.56M federal and $1.61M in New Jersey GIT. The NJ portion alone, which did not exist before 2026, adds meaningful new value to the §1202 planning analysis for every NJ-resident founder who holds qualifying stock.

Holders of pre-2026 stock: what you need to check now

A4455's retroactive-disposition rule means that founders and investors who have been holding QSBS for years — waiting out the 5-year clock, or simply not yet ready to sell — may have significant new state tax savings available starting in 2026. The key questions to review if you hold QSBS acquired before January 1, 2026:

Is the federal §1202 holding period satisfied?

For stock issued before July 4, 2025, the original §1202 rules apply: you need a 5-year hold for the 100% exclusion. If you purchased shares in early 2021 and have held them continuously, the 5-year mark arrives in early 2026 — right when NJ conformity kicks in. Founders in this situation should model the NJ savings as part of any 2026 sale-timing decision. See the holding period guide for how the clock starts for ISOs, RSAs, and SAFEs, and the 83(b) election guide for why the clock runs from grant for restricted shares when the election was filed.

Was the stock issued by a qualifying C corporation?

The federal §1202 qualification tests all apply — NJ conformity does not soften them. The company must have been a domestic C corporation at the time of issuance, have had gross assets below $50 million at the time of original issuance (or $75 million for post-July 4, 2025 stock under OBBBA), and operated an active qualified trade or business (not an excluded field such as health services, financial services, or law). Review the qualification requirements guide before assuming existing shares qualify. See the LLC and S-Corp guide if your company converted entity types.

Were shares acquired by original issuance?

Section 1202 requires original issuance directly from the company — shares purchased in a secondary market transaction from another shareholder do not qualify. This applies whether you are a founder who received shares at incorporation, an employee who exercised options, or an angel who invested in a priced equity round. Secondary market purchases are disqualified. See the angel investor guide for how the gross assets timing test works across funding rounds.

Section 1045 rollover holders: If you previously sold QSBS before the 5-year mark and rolled the gain into replacement QSBS under IRC §1045, New Jersey's 2026 conformity also applies to the replacement stock — holding period tacking applies for §1202 purposes. For NJ founders who used the 1045 rollover specifically to defer a pre-2026 NJ tax bill, re-check whether the replacement stock now qualifies for the NJ exclusion on a future sale. See the Section 1045 guide.

New Jersey's startup ecosystem: industry exclusion traps to know

New Jersey is home to one of the largest life-sciences ecosystems in the United States, with significant concentrations of pharmaceutical and biotech companies in the Princeton–Trenton–New Brunswick corridor, financial services and fintech firms in Jersey City and Hoboken, and technology and professional services companies throughout the Newark and suburban commuter markets. Several of these sectors intersect with Section 1202's excluded-industry rules.5

Life sciences and pharma: where the lines are drawn

Section 1202(e)(3) excludes businesses "in the field of health" — interpreted to cover companies whose core business is the performance of health services, not companies whose product is technology or manufactured goods for the healthcare sector. For New Jersey's startup ecosystem, the key distinction:

Fintech and financial services in Jersey City and Hoboken

Section 1202(e)(3)(A) explicitly excludes "financial services" and "brokerage services," and §1202(e)(3)(B) separately excludes banking, insurance, financing, leasing, and investing businesses. For the fintech companies based across the Hudson River from Manhattan, the key question is whether the business is a "technology company that serves financial services" or a "financial services company."

See the excluded industries guide for the full statutory analysis and borderline-case breakdown. A company that describes itself as "fintech" or "healthtech" may qualify or may not — the §1202 analysis turns on what the business actually does, not how it is described in a pitch deck or press release.

New Jersey versus neighboring states: QSBS comparison

FeatureNew JerseyNew YorkPennsylvaniaMassachusettsCalifornia
§1202 exclusion at state level? Yes — A4455, Jan 2026 Yes — rolling conformity No — non-conforming Yes — conforms since 2022 (TIR 23-5) No — repealed 2013
State tax on QSBS-excluded gain? $0 (for 2026+ dispositions) $0 (state + NYC) Full rate — 3.07% flat $0 (with rolling-conformity caveat on OBBBA) Full rate — up to 13.3%
Top marginal state rate 10.75% (income > $1M) ~10.9% state + 3.876% NYC 3.07% flat 5% (+ 4% millionaires surtax on income > $1.1M) 13.3% (income > $1M)
Preferential LTCG rate at state level? No — gains taxed as ordinary income No — gains taxed as ordinary income No — flat rate on all income 5% (no surcharge on CG) No — gains taxed as ordinary income
OBBBA $15M cap recognized at state? Yes — rolling conformity Yes — rolling conformity N/A — non-conforming Uncertain — static IRC date may preclude OBBBA changes N/A — non-conforming
Pre-2026 stock dispositions benefit from 2026 state conformity? Yes — applies to disposition date, not acquisition date N/A — always conformed N/A — non-conforming N/A — conformed since 2022 N/A — non-conforming
State where QSBS matters most for planning? Yes — high rate, recent change, retroactive benefit for existing holders Yes — but risk from 2026 decoupling proposal (withdrawn) Yes — small rate but still a cost on full gain Yes — OBBBA gap and millionaires surtax Critical — non-conforming, plan around it

New Jersey's position is now meaningfully different from Pennsylvania, its other major neighbor. A Pennsylvania-resident founder with the same qualifying QSBS exit still owes Pennsylvania income tax at 3.07% on the full gain — there is no Pennsylvania §1202 exclusion, and there are no current legislative proposals to change this. A New Jersey founder with a $10M excluded gain saves $1,075,000 in state tax that a Pennsylvania founder in the same situation does not.

The commuter question: NJ residents working in New York

Many New Jersey residents work in New York City and are subject to both New York State income tax (as nonresidents) and New Jersey GIT (as residents) on compensation earned in New York. The New York–New Jersey tax credit generally prevents full double-taxation of compensation income for NJ residents working in NY.

QSBS gain is different: Capital gains from the sale of private company stock are generally sourced to the state of residence of the shareholder, not the state where the company is located or where the shareholder works. A New Jersey-resident founder who sells QSBS issued by a New York–headquartered company will typically report that gain to New Jersey as the state of residence — not to New York as the state of the company's location. This means:
  • If the gain qualifies federally under §1202 and the sale occurs in 2026+, New Jersey excludes it under A4455.
  • New York would have jurisdiction over the gain only if the NJ-resident founder was a New York resident at the time of the sale — which NJ residents generally are not (though domicile is a facts-and-circumstances analysis).
  • NJ residents who commute to NYC and receive wage-sourced equity compensation (ISOs exercised while working in NY, or NSOs tied to NY employment) may have a New York-source income component — this is separate from the QSBS capital gain on the underlying stock and requires state-sourcing analysis.

If your equity has a compensation component — ISOs, NSOs, or RSAs granted and vested while working in New York — consult a tax professional on New York-source income apportionment before concluding that the NJ exclusion eliminates your state tax exposure entirely. See the ISO and QSBS guide for how the compensation-versus-capital-gain line is drawn for option-holder exits.

Planning priorities for New Jersey founders

1. Check whether you have pre-2026 QSBS that now qualifies for NJ exclusion

If you have held QSBS for five or more years and were previously deterred from selling partly because of the New Jersey state tax, your 2026 situation has changed. A $10M QSBS exit that previously triggered $1,075,000 in New Jersey GIT now triggers $0 — if the stock passes the eight federal §1202 qualification tests. Model the new NJ economics before deciding whether to continue holding or transact. See the QSBS exclusion calculator to estimate your potential exclusion, and the Section 1202 checklist to verify qualification.

2. Prioritize the holding period: reach 5 years before selling post-OBBBA stock

For stock issued after July 4, 2025, the OBBBA tiered exclusions apply in New Jersey (rolling conformity). A sale at 3 years gives 50%; at 4 years, 75%; at 5 years, 100%. The 28% federal rate trap on non-excluded gain at the 3-year and 4-year tiers is compounded by New Jersey GIT on the non-excluded portion at 10.75%. The total tax difference between a 4-year and 5-year hold on a $15M post-OBBBA exit exceeds $1.59M — the 5-year mark should be the dominant planning constraint if the company is approaching a liquidity event. See the holding period guide.

3. Verify the excluded-industry test before building any NJ QSBS strategy

New Jersey's life sciences, fintech, and healthcare sectors make the §1202(e)(3) excluded-industry analysis a non-optional first step. Have a qualified tax attorney confirm that your company's primary business activity clears the health, financial services, or reputation/skill exclusions before assuming §1202 applies. A company that is a Princeton biotech or a Jersey City payments startup occupies factual territory that requires a careful analysis. See the excluded industries guide.

4. Review gifting and trust strategies in light of the new NJ exclusion

The NJ exclusion now also benefits donees of QSBS stock under IRC §1202(h), assuming the donee is a New Jersey GIT filer. If you have been contemplating gifting QSBS shares to family members to stack exclusion caps — each donee gets their own §1202 exclusion limit — the NJ conformity amplifies the gifting benefit for all NJ-resident donees. The gift must occur before a definitive agreement or LOI is signed to preserve the exclusion for the donee. See the gifting and stacking guide and the trusts guide for how non-grantor trusts established in New Jersey interact with the GIT exclusion.

5. Document your New Jersey filing position clearly

A4455 is new law, and the New Jersey Division of Taxation has not yet issued extensive guidance on how to report the QSBS exclusion on the NJ-1040. For the 2026 tax year, the most defensible approach is to report the exclusion on Form NJ-1040 in the same manner it is reported federally — as a negative adjustment on the disposition schedule — and attach a schedule showing the federal §1202 exclusion calculation, the stock's issuance date, and the disposition date. Consider retaining the documentation recommended in the QSBS documentation guide — QSBS attestation letter, subscription agreement, 83(b) election if applicable, and company-provided gross assets certification — in case the Division of Taxation requests support for the exclusion.

Talk to a QSBS advisor about your New Jersey situation

New Jersey's 2026 conformity changes the calculus for every NJ-resident founder, investor, and employee holding qualifying QSBS. If you have been holding stock that clears the 5-year mark in 2026 or later, the NJ GIT exclusion is now available for the first time — and at a 10.75% rate, the state tax savings are material to any exit decision. An advisor who specializes in QSBS and founder liquidity can help you confirm qualification, model the NJ impact alongside the federal analysis, and coordinate the pre-transaction planning window.

Fee-only focus - No obligation - Privacy-minded matching - Built for seven-figure planning decisions

Sources

  1. New Jersey's prior non-conformity with §1202 and the list of non-conforming states (CA, PA, AL, MS, NJ): Kulzer & DiPadova — New Jersey GIT Adds IRC §1202 Exclusion for QSBS Gains; EisnerAmper — New Jersey to Allow Exclusion of Qualified Small Business Stock Gains. Prior to A4455, NJ imposed Gross Income Tax on all §1202 gain at rates up to 10.75%.
  2. A4455/S4503 signed June 30, 2025; effective for tax years beginning January 1, 2026; applies to dispositions on or after January 1, 2026 even for stock acquired before that date: Mintz — New Jersey Adopts QSBS Exclusion: A Game-Changer for In-State Investors and Founders; Withum — New Jersey Aligns with Federal QSBS Exclusion.
  3. Rolling (dynamic) conformity interpretation — A4455 adopts §1202 by reference without a static IRC date, incorporating OBBBA's July 4, 2025 amendments automatically: OlenderFeldman — Legislative Alert: QSBS / One Big Beautiful Bill Act / NJ Bill A4455/S4503; Brach Eichler — NJ Qualified Small Business Stock Conformity. OBBBA §1202 changes: IRC §1202(b)(1)(B) ($15M cap), §1202(b)(1)(A) (tiered exclusion), §1202(d)(1) ($75M gross assets threshold), all effective for stock issued after July 4, 2025.
  4. New Jersey Gross Income Tax rates 2026 — top marginal rate 10.75% on income above $1 million; no preferential capital gains rate; gains taxed as ordinary income: NJ Division of Taxation — Income Tax Rates; Tax Foundation — 2026 New Jersey Tax Rates & Rankings (confirming 4th-highest individual income tax rate in the nation at 10.75%).
  5. New Jersey life sciences and startup ecosystem — Princeton BioLabs, pharmaceutical manufacturing concentration in central NJ, fintech in Jersey City and Hoboken: Choose NJ — Life Sciences in New Jersey; Builds Bio+ — New Jersey Inaugural Symposium for Life Science Innovation and Development (March 2026). §1202(e)(3) excluded-industry statutory text: 26 U.S. Code § 1202 — Cornell LII.

Values and legislative status verified as of July 2026. A4455/S4503 effective January 1, 2026 — New Jersey GIT exclusion applies to dispositions on or after that date. Rolling conformity interpretation is based on the dynamic statutory reference adopted by A4455; the New Jersey Division of Taxation has not yet issued formal administrative guidance on OBBBA interaction. Industry exclusion analysis under §1202(e)(3) requires review of specific company facts. Consult a fee-only financial advisor and a qualified tax professional before relying on the §1202 or NJ GIT exclusion for a specific transaction.